Cooley M&A

JANUARY 25, 2023

Although there were 104 initial public offerings of biotechnology companies in 2021 that raised nearly $15 billion in funds, 2022 saw only 22 such IPOs collectively raising less than $2 billion. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Growth Business

SEPTEMBER 13, 2023

DN Capital’s previous funds are top performers and the firm is one of the lead investors in companies such as Endeca (sold to Oracle), Shazam (one of the world’s leading mobile app), Auto1 (world’s largest used car marketplace), Purplebricks (IPO London) and Quandoo (sold to Recruit).

Capital 52

Capital Business Funds Investment 52

Mergers and Inquisitions

APRIL 10, 2024

Others with a broader “entertainment” focus include Atairos, Causeway, The Chernin Group, Elysian Park (more of a VC), Fiume Capital, and Zelnick Media. Larger, Diversified Funds That Also Invest in Sports As sports investing became more popular, many firms with a traditional TMT or media/entertainment focus also got involved.

Private Equity 103

Private Equity Equities Funds Entertainment 103

Cooley M&A

FEBRUARY 1, 2024

Private equity slowed but not stopped by financing environment Despite record amounts of dry powder accumulating for sponsors, high financing costs, persistent valuation gaps and a closed tech IPO market led to a significant decrease in private equity M&A activity in 2023. Despite some isolated bright spots – such as Thoma Bravo’s $10.7

M&A 59

M&A Mergers and Acquisitions Private Equity Equities 59